FDA Warns Mint Med Over White-Labeled Compounded GLP-1 Product Labels
On June 8, 2026, FDA issued a warning letter to Glow Medispa, LLC dba Mint Med after a May 2026 review of mintmed.com, which offers compounded semaglutide and tirzepatide products. FDA says the compounded semaglutide and tirzepatide products displayed on the site identify "Mint Med" on the pictured label, "suggesting Mint Med is the compounder of those drugs when in fact it is not," which FDA says renders the products misbranded under sections 502(a) and 502(bb) of the FD&C Act. FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
Source: FDA original ↗